High-throughput interrogation of programmed ribosomal frameshifting in human cells

Martin Mikl, Yitzhak Pilpel, Eran SegalbioRxiv 2018 · DOI

Abstract

Programmed ribosomal frameshifting is the controlled slippage of the translating ribosome to an alternative frame. This tightly regulated process is widely employed by human viruses such as HIV and SARS coronavirus and is critical for their life cycle and virulence. It is also utilized from yeast to human to implement a feedback control mechanism to regulate polyamine levels. Here, we developed a high-throughput, fluorescence-based approach to assess the frameshifting potential of a sequence. We designed and tested >12,000 sequences based on 15 viral and human frameshifting events, allowing us to elucidate the rules governing ribosomal frameshifting in a systematic way and to discover novel regulatory inputs based on amino acid properties and tRNA availability. We assessed the natural variation in HIV gag-pol frameshifting rates by testing >500 clinical isolates and identified subtype-specific differences as well as associations between viral load in patients and the optimality of gag-pol frameshifting rates. We further devised computational models that accurately predict frameshifting potential (up to auROC=0.93) and frameshifting rates (up to Pearson r=0.81) of novel variants, including subtle differences between HIV clinical isolates (r=0.60). Taken together, this systematic approach can contribute to the development of antiviral agents acting on programmed ribosomal frameshifting.

Introduction

In the standard "central dogma" of biology, ribosomes read mRNA in strict three-letter increments known as codons. However, certain genetic sequences trigger Programmed Ribosomal Frameshifting (PRF), where the ribosome intentionally slips forward or backward by one or two nucleotides. This mechanism allows a single mRNA to encode multiple proteins, a strategy essential for the life cycles of viruses like HIV and coronaviruses. While PRF has been studied for decades, our understanding has been limited to individual "case studies." This research moves beyond low-throughput experiments to a large-scale, systematic interrogation of thousands of potential frameshifting sites to map the underlying regulatory rules.

Methods

The researchers developed a Massively Parallel Reporter Assay (MPRA) to quantify PRF efficiency in human K562 cells. They synthesized a library of over 13,000 unique DNA oligonucleotides, including variations of 15 known viral and human PRF sites (such as HIV-1, SARS-CoV, and human OAZ1) and 581 clinical isolates of HIV to study natural variation.

Experimental workflow for measuring frameshifting using MPRA and FACS-seq.

As illustrated in the experimental design, each sequence was placed between two fluorescent markers: mCherry (expressed in the normal frame) and GFP (placed in an alternative reading frame). If the ribosome slips at the test sequence, it produces GFP. These reporters were integrated into a specific genomic "safe harbor" (AAVS1) to ensure single-copy expression per cell. The cells were then sorted into 16 bins using FACS-seq based on their GFP/mCherry ratio, and Next-Generation Sequencing (NGS) was used to quantify variant distribution and calculate frameshifting rates.

Key Insights and Results

The assay provided a high-resolution map of frameshifting potential across diverse sequences, revealing that PRF is governed by complex, context-dependent rules.

Frameshifting rates for -1 and +1 PRF events across various viral and human sequences.

Context and Upstream Regulation

The study found that there is no "universally perfect" slippery sequence; instead, sites are highly optimized for their specific genetic neighborhood. Beyond the traditional downstream "roadblock" (like an RNA pseudoknot), upstream elements were found to be significant. Specifically, the presence of charged amino acids or codons with low tRNA availability can cause the ribosome to stall, influencing the likelihood of a slip.

HIV Fitness Landscape

HIV frameshifting rates in clinical isolates were found to cluster around an "optimal" rate. Patients with the highest viral loads tended to have frameshifting rates closest to the wild-type lab strain, suggesting the virus fine-tunes this mechanism to maximize replication success. Significant differences were also noted between HIV subtypes (e.g., Subtype B vs. Subtype C).

Predictive Power

Computational models (XGBoost) trained on features like RNA secondary structure (Minimum Free Energy) and tRNA availability (tAI) were remarkably accurate. They achieved an auROC of 0.93 for classifying frameshifting potential and a Pearson correlation of r=0.81 for predicting actual rates. The assay was sensitive enough to detect subtle differences even among highly similar HIV clinical isolates (r=0.60).

Conclusion

This high-throughput approach provides a systematic understanding of the rules governing ribosomal frameshifting. By identifying how viruses like HIV optimize these "glitches" for fitness, this platform opens new avenues for developing antiviral therapies that specifically disrupt viral PRF without affecting host cell function.

Summary updated

Abstract

Summary Programmed ribosomal frameshifting is the controlled slippage of the translating ribosome to an alternative frame. This tightly regulated process is widely employed by human viruses such as HIV and SARS coronavirus and is critical for their life cycle and virulence. It is also utilized from yeast to human to implement a feedback control mechanism to regulate polyamine levels. Here, we developed a high-throughput, fluorescence-based approach to assess the frameshifting potential of a sequence. We designed and tested >12,000 sequences based on 15 viral and human frameshifting events, allowing us to elucidate the rules governing ribosomal frameshifting in a systematic way and to discover novel regulatory inputs based on amino acid properties and tRNA availability. We assessed the natural variation in HIV gag-pol frameshifting rates by testing >500 clinical isolates and identified subtype-specific differences as well as associations between viral load in patients and the optimality of gag-pol frameshifting rates. We further devised computational models that accurately predict frameshifting potential (up to auROC=0.93) and frameshifting rates (up to Pearson r=0.81) of novel variants, including subtle differences between HIV clinical isolates (r=0.60). Taken together, this systematic approach can contribute to the development of antiviral agents acting on programmed ribosomal frameshifting.
BibTeX
@misc{mikl2018high,
  author = {Martin Mikl and Yitzhak Pilpel and Eran Segal},
  title = {{High-throughput interrogation of programmed ribosomal frameshifting in human cells}},
  year = {2018},
  doi = {10.1101/469692},
  howpublished = {bioRxiv},
}
Figure